Sequencing giant Illumina on Thursday announced that it will take a $1.47 billion hit in the second quarter of 2024 related to the recently completed spinoff of cancer testing company Grail.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,